Skip to main content
. 2014 May 5;16(8):1137–1145. doi: 10.1093/neuonc/nou056

Table 2.

Summary of literature reporting overall survival related to CNS tumors in clinical trials, split by ages <3 y and 3–14 y

Tumor Type Survival, %
Trials22,24,26,27,29,30,4257 Present Study
<3 y Low-grade glioma (WHO grades I/II) 5y 95 (1–3 y old, 95 <1 y old, 76)
High-grade glioma (WHO grades III/IV) 5y 31–66 SEER 5y 51
10y 38 NRCT 5y 35
SEER 10y 51
NRCT 10y 35
Ependymoma 5y 63 SEER 5y 67
NRCT 5y 56
SEER 10y 62
NRCT 10y 49
Embryonal (medulloblastoma, sPNET) SEER 5y 48
NRCT 5y 33
Medulloblastoma 5y 43 SEER 5y 52
NRCT 5y 42
SEER 10y 49
NRCT 10y 42
sPNET 5y 31 SEER 5y 43
NRCT 5y 11
SEER 10y 41
NRCT 10y 11
3–14 y Low-grade glioma (WHO grades I/II) 5y 86
10y 94
High-grade glioma (WHO grades III/IV) 2y 21 SEER 2y 22
5y 19 NRCT 2y 13
SEER 5y 22
NRCT 5y 10
Ependymoma 5y 60–85 SEER 5y 76
NRCT 5y 71
SEER 10y 74
NRCT 10y 63
Embryonal (medulloblastoma, sPNET) SEER 5y 73
NRCT 5y 67
Medulloblastoma 5y 87 SEER 5y 76
10y 81 NRCT 5y 71
SEER 10y 74
NRCT 10y 64
sPNET 5y 73 SEER 5y 65
NRCT 5y 45
SEER 10y 61
NRCT 10y 36

Abbreviation: WHO, World Health Organization.